Fig. 1

Consort diagram. From August 2011 to April 2019, a total of 486 patients with MBC underwent treatment at the Osaka City University Hospital. In this study, only 88 patients who underwent chemotherapy using eribulin were included, and 380 patients who were administered with other drug therapies, such as endocrine therapy or other chemotherapy regimens, and 18 patients who dropped out due to surgery or adverse events were excluded